Wednesday June 25, 7:00 am ET
Expert in Virus-Cell Interactions had Proposed Blocking them as a Possible Treatment
Press Release Source: NanoViricides, Inc.
WEST HAVEN, Conn.: NanoViricides, Inc. (Chart: NNVC.OB), (the “Company”) said that noted Yale University School of Medicine research physician, Thomas Lentz, MD, has agreed to join the NanoViricides’ Scientific Advisory Board (SAB).
In accepting the invitation, Dr. Lentz commented by email, “As you know, I was an early proponent of the possibility of treating viral infections by blocking the virus-receptor interaction. While most attempts at putting this into practice have not been successful, I believe the innovative approach employed by NanoViricides has great potential.”
Professor Lentz’s research has laid the early foundations for developing anti-viral therapies by blocking virus-cell receptor interactions. His work on the binding of rabies virus to the nicotinic acetylcholine receptor has helped in the creation of a rabies-specific nanoviricide. In addition, his extensive studies on the classification of viruses and of their cellular receptors into broad groups provided the basis for the broad-spectrum nanoviricides that the Company is developing at present as potent therapeutics against a large number of viruses.
Dr. Lentz, whose current title is Senior Research Scientist and Professor Emeritus of Cell Biology was previously also Associate Dean for Admissions and Financial Aid at the School of Medicine (http://www.cellbiology.yale.edu/cellbio/html/faculty/t_lentz.shtml).
“It is needless to say that to have Professor Lentz join our SAB is indeed an honor,” commented Dr. Anil Diwan, President of the Company, adding, “We have already benefited substantially from his extensive research in the virus–cell interactions field. His association with the Company should help us tremendously in our mission of destroying viruses in the body and conquering viral diseases.”
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, EKC (epidemic kerato-conjunctivitis or severe pink eye disease), hepatitis C, rabies, dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.
Disclaimer: Long NNVC with my lowest purchase at $0.72. I may sell those shares at any time to book profits as I trade it to lower my cost basis. For my recommended buy and sell levels for trading, see "Kirk's Investment Newsletter." (Testimonials - Subscribe Now)